NCT02937558View on ClinicalTrials.gov

CSI-Glucagon for Prevention of Hypoglycemia in Children With Congenital Hyperinsulinism

PHASE2CompletedINTERVENTIONAL
Enrollment

5

Participants

Timeline

Start Date

October 31, 2016

Primary Completion Date

September 30, 2018

Study Completion Date

October 31, 2018

Conditions
Congenital Hyperinsulinism
Interventions
DRUG

Glucagon

Room-temperature-stable, non-aqueous injectable liquid formulation of synthetic glucagon peptide

OTHER

Placebo

Isotonic saline

Trial Locations (5)

63130

Washington University, St. Louis Children's Hospital, St Louis

76104

Cook Children's Medical Center, Fort Worth

77030

Baylor College of Medicine, Texas Children's Hospital, Houston

90095

UCLA Mattel Children's Hospital, Los Angeles

94143

UCSF School of Medicine, Division of Pediatric Endocrinology, San Francisco

Sponsors
All Listed Sponsors
collaborator

National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

NIH

lead

Xeris Pharmaceuticals

INDUSTRY